价格表现：近7日（2026年2月16日至2月20日），百心安-B股价区间下跌3.20%，其中2月16日收盘报 5.50港元（单日跌2.14%），2月20日收盘报5.44港元（单日跌1.09%）。股价波动受港股大盘走弱（恒 生指数同期跌2.83%）及医疗板块调整影响。 股票近期走势 经济观察网 华鑫证券在2026年2月15日发布的医药行业周报中，将百心安-B（02185.HK）列为医疗器械 领域高值耗材出口突破的值得关注标的，反映出机构对其在海外市场拓展潜力的认可。该报告同时指 出，医药行业整体聚焦原料药供给变化、GLP-1减重领域合作及小核酸技术突破，百心安-B作为医疗设 备企业，可能间接受益于行业创新趋势。 技术指标：截至2月20日，股价低于5日、10日及20日均线，MACD柱状图为负值，显示短期弱势；但布 林带下轨（5.256港元）提供部分支撑，KDJ指标中J线降至29.5，接近超卖区域。 机构观点 资金流向：2月20日散户资金净流入80,403港元，主力资金无显著活动，换手率仅0.02%，市场交投清 淡。 华鑫证券在2026年2月15日发布的医药行业周报中，将百心安-B（02185.HK）列为医疗器械领 ...

Group 1: Core Insights - The stock price of Baixinan-B (02185.HK) experienced a significant decline of 9.24%, closing at HKD 5.40, underperforming against the Hang Seng Index and the medical device sector amid a general downturn in the Hong Kong stock market on February 12, 2026 [1] Group 2: Industry Sector Situation - The overall performance of medical stocks in Hong Kong was weak, with Baixinan-B and GUANZE MEDICAL among the top decliners, indicating market caution towards the medical sector potentially influenced by changes in industry policy expectations or capital flows [1] Group 3: Financial and Technical Analysis - Despite a positive MACD histogram suggesting short-term momentum improvement, the stock price remains below key moving averages (5-day, 20-day), and the narrowing Bollinger Bands indicate reduced volatility, leading some investors to take profits or avoid short-term risks; the trading volume was 516,400 shares with a turnover rate of 0.22%, reflecting low liquidity that may amplify price fluctuations [2] Group 4: Industry Policy and Environment - The National Healthcare Security Administration announced on February 10, 2026, that a new round of high-value medical consumables procurement will take place, which, while not directly affecting Baixinan-B's core products, raises concerns about long-term price pressures on cardiovascular interventional consumables, potentially impacting market sentiment; recent price adjustments in Fujian and Shandong provinces may also contribute to uncertainty in industry policies, prompting cautious capital behavior [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 公司名稱: 上海百心安生物技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02185 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 235,703,422 | RMB | | 1 RMB | | 235,703,422 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 235,703,422 | RMB | ...

安通与柏盛就Iberis RDN系统的商业化达成战略伙伴关系，相关合作涵盖多个地区，包括但不限于欧盟 国家、亚太地区及拉丁美洲(LATAM)地区。 截至本公告日期，Iberis RDN系统是全球唯一获准使用经桡动脉方法(TRA)和经股动脉入路方法(TFA)的 肾神经阻断(RDN)产品。TRA使RDN更安全、更有效、更便宜。集团的最终目标是为全球患者提供门诊 RDN手术。安通已于2016年于欧洲取得Iberis RDN系统的CE标志。 百心安-B(02185)发布公告，最近，本公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis多极 肾动脉射频消融导管系统(Iberis RDN系统)已在印度尼西亚注册。该注册得到柏盛国际集团有限公司(柏 盛)及安通的共同支持。 ...

截至本公告日期，IberisRDN系统是全球唯一获准使用经桡动脉方法(TRA)和经股动脉入路方法(TFA)的 肾神经阻断(RDN)产品。TRA使RDN更安全、更有效、更便宜。集团的最终目标是为全球患者提供门诊 RDN手术。安通已于2016年于欧洲取得IberisRDN系统的CE标志。 安通与柏盛就IberisRDN系统的商业化达成战略伙伴关系，相关合作涵盖多个地区，包括但不限于欧盟 国家、亚太地区及拉丁美洲(LATAM)地区。 智通财经APP讯，百心安-B(02185)发布公告，最近，本公司附属公司上海安通医疗科技有限公司(安通) 研发的Iberis多极肾动脉射频消融导管系统(Iberis RDN系统)已在印度尼西亚注册。该注册得到柏盛国际 集团有限公司(柏盛)及安通的共同支持。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不會就本公告全部或任何部分內容而產生或因依賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 Shanghai Bio-heart Biological Technology Co., Ltd. 上海百心安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：2185） 自願公告 IBERIS® RDN系統在印度尼西亞洲註冊 本 公 告 乃 由 上 海 百 心 安 生 物 技 術 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，以 向 本 公 司 股 東 及 潛 在 投 資 者 提 供 有 關 本 集 團 最 新 業 務 發 展 情 況 的 最 新 資 料。 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，最 近，本 公 司 附 屬 公 司 上 海 安 通 醫 療 科 技 有 限 公 司（「安 通」）研 發 的 ...

Core Insights - The coronary access devices are essential consumables for percutaneous coronary intervention (PCI) surgeries, directly impacting surgical outcomes and complication control [1][6] - The industry is supported by a series of policies in China, including centralized procurement, innovation approvals, and grassroots medical construction, laying a solid foundation for high-quality development [6][10] - The number of coronary artery disease patients is steadily increasing globally and in China, with projections indicating 220 million patients worldwide and 27.879 million in China by 2024, highlighting significant growth potential for the industry [10] Industry Overview - Coronary access devices are specialized medical equipment and consumables used in PCI surgeries to establish and maintain access from the body surface to the coronary arteries, ensuring the smooth execution of angiography, balloon dilation, and stent implantation [1][6] - The devices are categorized into four main types: puncture devices, catheter systems, sheath sets, and auxiliary devices for pressure monitoring and vascular closure [3][4] Development Background - The development of coronary access devices is crucial for reducing cardiovascular disease mortality, enhancing medical accessibility, and promoting high-end device localization [6][8] - Recent policies in China aim to improve centralized procurement mechanisms, accelerate innovation device approvals, and standardize medical insurance payments, providing guidance for industry development [6][10] Market Analysis - The global coronary balloon dilatation catheter market is expanding, with functional balloons growing at a faster rate; the market size is expected to increase from $560 million in 2020 to $960 million in 2024, with a compound annual growth rate (CAGR) of 8.49% [12][14] - In China, the market is characterized by structural adjustments and rapid growth, with the general balloon market experiencing a temporary decline due to centralized procurement but expected to rebound, while functional balloons are projected to grow significantly, with a CAGR of 19.28% from 2024 to 2028 [14][16] Competitive Landscape - The competitive landscape of the coronary access device industry is tiered, with foreign companies dominating the high-end market while domestic leaders are accelerating their market penetration; by 2024, domestic companies are expected to capture 54.9% of the coronary balloon market [14][15] Future Trends - The industry is expected to evolve along three main directions: technological upgrades, deepening domestic substitution, and expansion of grassroots markets [16] - Innovations such as biodegradable materials and smart functions will drive high-end product iterations, while local companies will enhance core component localization through material and manufacturing process advancements [17][18] - The promotion of tiered diagnosis and treatment will reshape market demand, with a growing need for cost-effective and standardized products suitable for grassroots settings [18]

| 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 百心安-B(02185) | Winning Powerful Limited | 好仓 | 4616.56 万股 | 4617.56 万股 | 19.59%(最新) 19.59%(前次) | | 百心安-B(02185) | Wang Philip Li | 好仓 | 8534.77 万股 | 8535.77 万股 | 36.21%(最新) | | | | | | | 36.21%(前次) | 智通财经APP获悉，百心安-B(02185)于2026年1月22日进行了最新股东权益披露。 备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 ...

备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 智通财经APP获悉，百心安-B(02185)于2026年1月21日进行了最新股东权益披露。 | 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 百心安-B(02185) | Wang Philip Li | 好仓 | 8533.77 万股 | 8534.77 万股 | 36.21%(最新) 36.21%(前次) | | 百心安-B(02185) | Winning Powerful | 好仓 | 4615.56 万股 | 4616.56 万股 | 19.59%(最新) | | | Limited | | | | 19.58%(前次) | ...

Core Viewpoint - The latest shareholder equity disclosures for Baixinan-B (02185), Tongjing New Energy (08326), and Shisi Pharmaceutical Group (02005) were conducted on January 8, 2026, revealing changes in shareholdings among key institutional investors [1]. Group 1: Baixinan-B (02185) - Wang Philip Li increased his holdings from 85.2477 million shares to 85.2577 million shares, maintaining a holding percentage of 36.17% [2]. - Winning Powerful Limited also slightly increased its holdings from 46.0656 million shares to 46.0756 million shares, with a holding percentage of 19.55% [2]. Group 2: Tongjing New Energy (08326) - Well Mount Holdings Limited raised its holdings from 97.975 million shares to 101 million shares, increasing its holding percentage from 7.98% to 8.22% [2]. Group 3: Shisi Pharmaceutical Group (02005) - Qu Jiguang increased his holdings from 1.23 billion shares to 1.231 billion shares, with a holding percentage rising from 41.68% to 41.72% [2].